ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...

Valued at a market cap of $336 billion, AbbVie Inc. (ABBV) is a global biopharmaceutical company dedicated to developing ...